Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproate acid plus doxorubicin in refractory or recurrent malignant mesothelioma
2006-001443-63Phase 2Completed
- Sponsor
- European Lung Cancer Working Party
- Start
- Apr 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and valproic acid in mesothelioma, sponsored by European Lung Cancer Working Party. Primary endpoint: Objective response rate. Started Apr 2006; status: completed.
02
Drugs
doxorubicinvalproic acid
03
Conditions
mesothelioma
Beyond the preview
Go deeper on 2006-001443-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001443-63.